Automate Your Wheel Strategy on ZTS
With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZTS
- Rev/Share 21.0851
- Book/Share 11.1818
- PB 13.2273
- Debt/Equity 1.3645
- CurrentRatio 1.7597
- ROIC 0.2232
- MktCap 65549051426.0
- FreeCF/Share 4.9854
- PFCF 29.5399
- PE 25.2039
- Debt/Assets 0.469
- DivYield 0.0131
- ROE 0.5321
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZTS | Leerink Partners | Outperform | Market Perform | -- | $155 | July 17, 2025 |
| Downgrade | ZTS | Stifel | Buy | Hold | -- | $160 | June 18, 2025 |
News
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Positive
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share.
Read More
Zoetis forecasts 2025 profit, revenue below estimates; shares fall
Published: February 13, 2025 by: Reuters
Sentiment: Negative
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading.
Read More
Zoetis Reports Fourth Quarter and Full Year 2024 Results
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter of 2024 increased 6% compared with the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $581 mill.
Read More
About Zoetis Inc. (ZTS)
- IPO Date 2013-02-01
- Website https://www.zoetis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kristin C. Peck
- Employees 13800